信迪利单抗联合贝伐珠单抗生物类似药对比索拉非尼一线治疗不可切除肝细胞癌:ORIENT-32随机开放2-3期研究
ORIENT-32研究在中国50个中心入组595例不可切除HBV相关肝细胞癌患者,3期部分按2:1随机接受信迪利单抗联合IBI305或索拉非尼。联合组3-4级高血压发生率14% vs 6%。
要点
- 信迪利单抗联合IBI305一线治疗HBV相关不可切除肝癌,PFS和OS均显著优于索拉非尼。
- 联合组3-4级高血压发生率14%,高于索拉非尼组的6%。
核心结论
- 信迪利单抗联合IBI305对比索拉非尼一线治疗中国不可切除HBV相关肝细胞癌,显著改善OS和PFS,安全性可接受。
研究设计与样本
- 随机、开放标签、2-3期研究,在中国50个临床中心开展。
- 3期部分将571例患者按2:1随机分配至信迪利单抗联合IBI305组(n=380)或索拉非尼组(n=191)。
- 2期安全性导入部分入组24例患者,接受信迪利单抗200 mg每3周联合IBI305 15 mg/kg每3周。
- 3期索拉非尼用法为400 mg口服每日两次。
- 主要终点为3期部分OS和IRRC评估的PFS(RECIST 1.1,ITT人群)。
主要发现
- 最常见3-4级治疗 emergent 不良事件为高血压(联合组55/380例,14%;索拉非尼组11/185例,6%)和手足综合征(联合组0例;索拉非尼组22/185例,12%)。
- 联合组123例(32%)和索拉非尼组36例(19%)发生严重不良事件;导致死亡的治疗相关不良事件分别为6例(2%)和2例(1%)。
临床怎么用
- 对于中国不可切除HBV相关肝细胞癌且无既往系统治疗、ECOG PS 0-1的患者,可考虑信迪利单抗联合IBI305作为一线治疗选择。
- 治疗期间需重点监测高血压等不良事件,联合组3-4级高血压发生率高于索拉非尼组。
局限性
- 研究仅纳入中国HBV相关肝细胞癌患者,结果外推至其他病因或地区人群需谨慎。
- OS数据来自首次中期分析,联合组中位OS尚未达到,长期随访仍在进行中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: China has a high burden of hepatocellular carcinoma, and hepatitis B virus (HBV) infection is the main causative factor. Patients with hepatocellular carcinoma have a poor prognosis and a substantial unmet clinical need. The phase 2-3 ORIENT-32 study aimed to assess sintilimab (a PD-1 inhibitor) plus IBI305, a bevacizumab biosimilar, versus sorafenib as a first-line treatment for unresectable HBV-associated hepatocellular carcinoma. METHODS: This randomised, open-label, phase 2-3 study was done at 50 clinical sites in China. Patients aged 18 years or older with histologically or cytologically diagnosed or clinically confirmed unresectable or metastatic hepatocellular carcinoma, no previous systemic treatment, and a baseline Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 were eligible for inclusion. In the phase 2 part of the study, patients received intravenous sintilimab (200 mg every 3 weeks) plus intravenous IBI305 (15 mg/kg every 3 weeks). In the phase 3 part, patients were randomly assigned (2:1) to receive either sintilimab plus IBI305 (sintilimab-bevacizumab biosimilar group) or sorafenib (400 mg orally twice daily; sorafenib group), until disease progression or unacceptable toxicity. Randomisation was done using permuted block randomisation, with a block size of six, via an interactive web response system, and stratified by macrovascular invasion or extrahepatic metastasis, baseline α-fetoprotein, and ECOG performance status. The primary endpoint of the phase 2 part of the study was safety, assessed in all patients who received at least one dose of study drug. The co-primary endpoints of the phase 3 part of the study were overall survival and independent radiological review committee (IRRC)-assessed progression-free survival according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 in the intention-to-treat population. The study is registered with ClinicalTrials.gov, NCT03794440. The study is closed to new participants and follow-up is ongoing for long-term outcomes. FINDINGS: Between Feb 11, 2019 and Jan 15, 2020, we enrolled 595 patients: 24 were enrolled directly into the phase 2 safety run-in and 571 were randomly assigned to sintilimab-bevacizumab biosimilar (n=380) or sorafenib (n=191). In the phase 2 part of the trial, 24 patients received at least one dose of the study drug, with an objective response rate of 25·0% (95% CI 9·8-46·7). Based on the preliminary safety and activity data of the phase 2 part, in which grade 3 or worse treatment-related adverse events occurred in seven (29%) of 24 patients, the randomised phase 3 part was started. At data cutoff (Aug 15, 2020), the median follow-up was 10·0 months (IQR 8·5-11·7) in the sintilimab-bevacizumab biosimilar group and 10·0 months (8·4-11·7) in the sorafenib group. Patients in the sintilimab-bevacizumab biosimilar group had a significantly longer IRRC-assessed median progression-free survival (4·6 months [95% CI 4·1-5·7]) than did patients in the sorafenib group (2·8 months [2·7-3·2]; stratified hazard ratio [HR] 0·56, 95% CI 0·46-0·70; p<0·0001). In the first interim analysis of overall survival, sintilimab-bevacizumab biosimilar showed a significantly longer overall survival than did sorafenib (median not reached [95% CI not reached-not reached] vs 10·4 months [8·5-not reached]; HR 0·57, 95% CI 0·43-0·75; p<0·0001). The most common grade 3-4 treatment-emergent adverse events were hypertension (55 [14%] of 380 patients in the sintilimab-bevacizumab biosimilar group vs 11 [6%] of 185 patients in the sorafenib group) and palmar-plantar erythrodysaesthesia syndrome (none vs 22 [12%]). 123 (32%) patients in the sintilimab-bevacizumab biosimilar group and 36 (19%) patients in the sorafenib group had serious adverse events. Treatment-related adverse events that led to death occurred in six (2%) patients in the sintilimab-bevacizumab biosimilar group (one patient with abnormal liver function, one patient with both hepatic failure and gastrointestinal haemorrhage, one patient with interstitial lung disease, one patient with both hepatic faliure and hyperkalemia, one patient with upper gastrointestinal haemorrhage, and one patient with intestinal volvulus) and two (1%) patients in the sorafenib group (one patient with gastrointestinal haemorrhage and one patient with death of unknown cause). INTERPRETATION: Sintilimab plus IBI305 showed a significant overall survival and progression-free survival benefit versus sorafenib in the first-line setting for Chinese patients with unresectable, HBV-associated hepatocellular carcinoma, with an acceptable safety profile. This combination regimen could provide a novel treatment option for such patients. FUNDING: Innovent Biologics. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.
引用
- Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. Lancet Oncol. 2021. PMID: 34143971. doi:10.1016/S1470-2045(21)00252-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。